Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Seeks Injunction Against Teva/Barr Allegra Generic

This article was originally published in The Pink Sheet Daily

Executive Summary

A Newark, N.J. federal judge has scheduled an Oct. 24 hearing on Sanofi’s request for a preliminary injunction or expedited trial in the underlying patent dispute.

You may also be interested in...



Allegra Authorized Generic Scripts Could Reach 40% By Year-End, Sanofi Says

Teva describes the launch of its generic fexofenadine as one of the firm’s “most successful.”

Allegra Authorized Generic Scripts Could Reach 40% By Year-End, Sanofi Says

Teva describes the launch of its generic fexofenadine as one of the firm’s “most successful.”

Barr Sees Rapid Uptake Of Allegra Generic, Downplays Impact From Competition

Barr/Teva's "at risk" generic of Sanofi-Aventis' fexofenadine antihistamine captures a 70% substitution rate with some large retailers in the first week after launch.

Related Content

Topics

UsernamePublicRestriction

Register

PS062924

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel